| |
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel CytoImmune's Puerto Rican clinical cell manufacturing facility’s success. Learn how your business can do the same.
|
|
Today’s Big NewsFeb 9, 2024 |
| By Max Bayer Roche is laying off employees within its product development team, with the total reductions slated to impact less than 6% of full-time employees in the unit. The pharma group reported 7% growth in its non-COVID business. |
|
|
|
By Gabrielle Masson The efficacy of Moderna’s investigational RSV vaccine appears to wane faster than GSK’s approved shot Arexvy, a revelation that sent the big biotech’s stock slipping. |
By Kevin Dunleavy CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries. |
By Max Bayer Kyverna's $319 million IPO offers more evidence that biotech's once-icy public markets are thawing. And investors are clearly clamoring for cell therapies aimed at autoimmune diseases. |
By Conor Hale In addition to other inventory reduction initiatives, the moves are expected to cost between $125 million and $150 million through the end of 2025. |
By Kevin Dunleavy Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday. |
By Nick Paul Taylor Takeda’s narcolepsy work has finally yielded a phase 2b win, albeit with a blemish. After axing one asset over liver toxicity, the Japanese drugmaker’s continued faith in the mechanism has been rewarded with a primary endpoint hit—but the midphase program only supports progression in one form of the disease. |
By Fraiser Kansteiner Despite some turbulence at Catalent, including an 11% sales drop for the quarter, investors still seem to be buzzed about the stock after this week’s announcement that Novo Holdings is buying out the CDMO for $16.5 billion. |
By Andrea Park A mounting wave of recent research argues that high-volume hemodiafiltration may significantly improve outcomes for people with kidney failure compared to standard hemodialysis treatments. |
By James Waldron After a string of IPO success stories for clinical-stage biotechs so far this year, two companies look set to test whether they can expect the same warm reaction on the public markets this morning despite not yet having a candidate in human trials. |
By Zoey Becker The oncology drug supply crisis has entered its second year, and doctors still face "impossible choices" without access to standard-of-care therapies, ASCO's chief medical officer, Dr. Julie Gralow, testified this week. At a congressional hearing, Gralow proposed recommendations that could help ease the situation. |
By Andrea Park Echoing a previous $50 million fundraising, the new proceeds bring Unlearn’s lifetime total to more than $130 million. It will be used to build out its staff, computing power and long-term R&D projects. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
